Perlmutter Cancer Center

The purpose of this study is find out if the if the investigational drug, pamrevlumab, can be used to treat pancreatic cancer. FibroGen, Inc. (FibroGen), the study sponsor, is responsible for developing pamrevlumab. Pamrevlumab is called “investigational” because the drug has not been approved by the U.S. Food and Drug Administration (FDA), or by any other health authority in any country, for doctors to prescribe to their patients. Pamrevlumab is a type of protein drug called a human monoclonal antibody. Monoclonal antibodies are similar to the antibodies that your body normally produces. Antibodies are made by your immune system and help you fight infections.